Method for determining optimum intraocular locations for drug delivery systems

Abstract

A method for determining the optimum location for placement of an intraocular implant containing used to treat an ocular condition, particularly implants comprised of a biodegradable polymer and a therapeutic agent for the treatment of retinal tissue.

1 .- 7 . (canceled) 
     
     
         8 . A method for treating age related macular degeneration with a drug delivery system, the drug delivery system comprising a therapeutic agent and a biodegradable polymer associated with the therapeutic agent, the method comprising the step of placing the drug delivery system in the vitreous at a position x that is 1.3 cm from the aqueous humor and 0.8 cm from the macula thereby treating the age related macular degeneration. 
     
     
         9 . The method of  claim 8 , wherein the drug delivery system is a biodegradable intraocular implant produced by an extrusion method. 
     
     
         10 . The method of  claim 9 , wherein the placing step is carried out using an applicator with a ½ inch needle comprising a canula, in which canula the implant resides, wherein the needle has a length designed to permit placement of the drug delivery system into the vitreous at the position x. 
     
     
         11 . The method according to any one of  claim 8  or  9 , wherein said therapeutic agent is a corticosteroid or an anti-VEGF antibody, wherein the corticosteroid is selected from the group consisting of fluocinolone, triamcinolone, and dexamethasone. 
     
     
         12 . The method according to  claim 11 , wherein said therapeutic agent is at least one member selected from the group consisting of dexamethasone and fluocinolone, and said biodegradable polymer comprises at least one member selected from the group consisting of polylactides (PLA), polyglycolides (PGA), poly(lactide co-glycolide (PLGA), polycaprolactone, polyanhydride, poly methyl vinyl ether maleic anhydride, polycarbonates, polyarylates, polydioxanone, polyhydroxyalkanoates, and chitosan. 
     
     
         13 . The method of  claim 11 , wherein the therapeutic agent is an anti-VEGF antibody.